Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977805 | 1.00 | TLR7 (0.41) | TLR7IL6 | |
| Trifluoroacetic Acid SCHEMBL566788 | 0.89 | TLR7 (0.39) | TLR7IL6 | |
| SCHEMBL31126581 | 0.88 | TLR7 (0.39) | TLR7IL6 | |
| SCHEMBL26347181 | 0.86 | TLR7 (0.46) | TLR7IL6 | |
| SCHEMBL2542341 | 0.86 | TLR7 (0.41) | TLR7IL6 | |
| SCHEMBL1146282 | 0.85 | PDE4B (0.34) | TLR7 | |
| SCHEMBL12157588 | 0.85 | NCF1 (0.34) | TLR7 | |
| SCHEMBL31124723 | 0.84 | SLC29A1 (0.35) | TLR7IL6 | |
| SCHEMBL31126593 | 0.82 | TLR7 (0.33) | TLR7IL6 | |
| SCHEMBL19049988 | 0.82 | NUDT1 (0.34) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | AMBRX, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-05-09 | — | — | US | disclosed |
| CN-111201228-B | 6-amino-7, 9-dihydro-8H-purin-8-one derivatives as Toll-like receptor 7 (TLR 7) agonists | 百时美施贵宝公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117736210-A | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-114805341-B | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-1939199-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008071976-A1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1928876-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | AstraZeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1928877-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | Astra Zeneca AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008004948-A1 | 8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| WO-2007034173-A1 | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007031726-A1 | PURINE DERIVATIVES HAVING IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150346-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | TLR7, TLR1, TLR8 | TLR7 1/4885IL6 490/4885 |
| US-20070190071-A1 | 9-Substituted 8-oxoadenine compound | IFNAR1, IL5, IFNG | TLR7 8/4885IL6 833/4885 |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TLR7 4/4885IL6 1194/4885 |
| US-12569566-B2 | Compositions containing, methods and uses of antibody-TLR agonist conjugates | TLR3, TLR2, TLR1 | TLR7 8/4885IL6 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.